Literature DB >> 12611941

Nicotine enhances the depressive actions of A beta 1-40 on long-term potentiation in the rat hippocampal CA1 region in vivo.

D B Freir1, C E Herron.   

Abstract

Hippocampal long-term potentiation (LTP) is a form of synaptic plasticity used as a cellular model of memory. Beta amyloid (A beta) is involved in Alzheimer's disease (AD), a neurode-generative disorder leading to cognitive deficits. Nicotine is also claimed to act as a cognitive enhancer. A beta is known to bind with high affinity to the alpha 7-nicotinic acetylcholine receptor (nAChR). Here we have investigated the effect of intracerebroventricular (i.c.v.) injection of the endogenous peptide A beta 1-40 on LTP in area CA1 of urethananesthetized rats. We also examined the effect of A beta 12-28 (i.c.v.), which binds with high affinity to the alpha 7-nAChR and the specific alpha 7-nAChR antagonist methyllycaconitine (MLA) on LTP. We found that A beta 12-28 had no effect on LTP, whereas MLA depressed significantly LTP, suggesting that activation of the alpha 7-nAChR is a requirement for LTP. Within the in vivo environment, where other factors may compete with A beta 12-28 for binding to alpha 7-nAChR, it does not appear to modulate LTP. To determine if the depressive action of A beta 1-40 on LTP could be modulated by nicotine, these agents were also co-applied. Injection of 1 or 10 nmol A beta 1-40 caused a significant depression of LTP, whereas nicotine alone (3 mg/kg) had no effect on LTP. Co-injection of nicotine with A beta 1-40 1 h prior to LTP induction caused a further significant depression of LTP compared with A beta 1-40 alone. These results demonstrate that nicotine enhances the deficit in LTP produced by A beta 1-40. This then suggests that nicotine may exacerbate the depressive actions of A beta on synaptic plasticity in AD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12611941     DOI: 10.1152/jn.00996.2002

Source DB:  PubMed          Journal:  J Neurophysiol        ISSN: 0022-3077            Impact factor:   2.714


  13 in total

1.  TC-2559 excites dopaminergic neurones in the ventral tegmental area by stimulating alpha4beta2-like nicotinic acetylcholine receptors in anaesthetised rats.

Authors:  Yun Wang; John L Sherwood; Colin P Miles; Gary Whiffin; David Lodge
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 2.  Regulation of synaptic transmission and plasticity by neuronal nicotinic acetylcholine receptors.

Authors:  Bruce E McKay; Andon N Placzek; John A Dani
Journal:  Biochem Pharmacol       Date:  2007-07-07       Impact factor: 5.858

Review 3.  Alzheimer's disease amyloid beta-protein and synaptic function.

Authors:  Tomas Ondrejcak; Igor Klyubin; Neng-Wei Hu; Andrew E Barry; William K Cullen; Michael J Rowan
Journal:  Neuromolecular Med       Date:  2009-09-16       Impact factor: 3.843

Review 4.  Nicotinic receptors, amyloid-beta, and synaptic failure in Alzheimer's disease.

Authors:  Sofia Jürgensen; Sergio T Ferreira
Journal:  J Mol Neurosci       Date:  2009-08-19       Impact factor: 3.444

Review 5.  Physiological roles of amyloid-beta and implications for its removal in Alzheimer's disease.

Authors:  Glenda M Bishop; Stephen R Robinson
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

6.  Differing time dependencies of object recognition memory impairments produced by nicotinic and muscarinic cholinergic antagonism in perirhinal cortex.

Authors:  Chris J Tinsley; Nadine S Fontaine-Palmer; Maria Vincent; Emma P E Endean; John P Aggleton; Malcolm W Brown; E Clea Warburton
Journal:  Learn Mem       Date:  2011-06-21       Impact factor: 2.460

7.  Long-Term Potentiation at CA3-CA1 Hippocampal Synapses with Special Emphasis on Aging, Disease, and Stress.

Authors:  Ashok Kumar
Journal:  Front Aging Neurosci       Date:  2011-05-20       Impact factor: 5.750

Review 8.  Targeting synaptic dysfunction in Alzheimer's disease therapy.

Authors:  Robert Nisticò; Marco Pignatelli; Sonia Piccinin; Nicola B Mercuri; Graham Collingridge
Journal:  Mol Neurobiol       Date:  2012-08-23       Impact factor: 5.590

9.  Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels.

Authors:  Patricia A Lawlor; Ross J Bland; Pritam Das; Robert W Price; Vallie Holloway; Lisa Smithson; Bridget L Dicker; Matthew J During; Deborah Young; Todd E Golde
Journal:  Mol Neurodegener       Date:  2007-06-09       Impact factor: 14.195

10.  Amyloid Beta peptides differentially affect hippocampal theta rhythms in vitro.

Authors:  Armando I Gutiérrez-Lerma; Benito Ordaz; Fernando Peña-Ortega
Journal:  Int J Pept       Date:  2013-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.